203 related articles for article (PubMed ID: 4823918)
1. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive.
Givens JR; Andersen RN; Wiser WL; Fish SA
J Clin Endocrinol Metab; 1974 May; 38(5):727-35. PubMed ID: 4823918
[No Abstract] [Full Text] [Related]
2. Daily serum follicle-stimulating hormone, luteinizing hormone, and plasma testosterone and androstenedione in hirsute women with polycystic sclerotic ovaries: effects of diethylstilbestrol and norethindrone acetats.
Daane TA; Dignam WJ; Frankland MV; Simmer HH; Parlow AF
Am J Obstet Gynecol; 1973 Oct; 117(3):392-9. PubMed ID: 4729733
[TBL] [Abstract][Full Text] [Related]
3. In vivo endocrine studies in adrenal rest tumor of ovary.
Parker CR; Servy E; McDonough PG; Mahesh VB
Obstet Gynecol; 1974 Sep; 44(3):327-32. PubMed ID: 4277531
[No Abstract] [Full Text] [Related]
4. [Stein-Leventhal syndrome. Personal cases].
Rapino P; Sabatino P; Della Lunga S; Marulli R
Minerva Med; 1982 Oct; 73(40):2793-800. PubMed ID: 6813772
[No Abstract] [Full Text] [Related]
5. Familial hyperthecosis: comparison of endocrinologic and histologic findings with polycystic ovarian disease.
Judd HL; Scully RE; Herbst AL; Yen SS; Ingersol FM; Kliman B
Am J Obstet Gynecol; 1973 Dec; 117(7):976-82. PubMed ID: 4759835
[No Abstract] [Full Text] [Related]
6. Letter: Serum testosterone in the polycystic ovary syndrome.
Givens JR; Andersen RN
Am J Obstet Gynecol; 1975 Apr; 121(8):1124-5. PubMed ID: 1119513
[No Abstract] [Full Text] [Related]
7. The utility and selection of laboratory tests in the diagnosis of the polycystic ovary syndrome.
Deutsch S; Krumholz B; Benjamin I
J Reprod Med; 1978 May; 20(5):275-82. PubMed ID: 671401
[TBL] [Abstract][Full Text] [Related]
8. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
10. Remission of acanthosis nigricans associated with polycystic ovarian disease and a stromal luteoma.
Givens JR; Kerber IJ; Wiser WL; Andersen RN; Coleman SA; Fish SA
J Clin Endocrinol Metab; 1974 Mar; 38(3):347-55. PubMed ID: 4360917
[No Abstract] [Full Text] [Related]
11. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
[TBL] [Abstract][Full Text] [Related]
12. Virilization in pregnancy associated with polycystic ovary disease.
Fayez JA; Bunch TR; Miller GL
Obstet Gynecol; 1974 Oct; 44(4):511-21. PubMed ID: 4370552
[No Abstract] [Full Text] [Related]
13. The effectiveness of two oral contraceptives in suppressing plasma androstenedione, testosterone, LH, and FSH, and in stimulating plasma testosterone-binding capacity in hirsute women.
Givens JR; Andersen RN; Wiser WL; Umstot ES; Fish SA
Am J Obstet Gynecol; 1976 Feb; 124(4):333-9. PubMed ID: 1251854
[TBL] [Abstract][Full Text] [Related]
14. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease.
Yen SS; Vela P; Rankin J
J Clin Endocrinol Metab; 1970 Apr; 30(4):435-42. PubMed ID: 5435284
[No Abstract] [Full Text] [Related]
15. Hyperthecosis: an inheritable form of polycystic ovarian disease.
Wilroy RS; Givens JR; Wiser WL; Coleman SA; Andersen RN; Summitt RL
Birth Defects Orig Artic Ser; 1975; 11(4):81-5. PubMed ID: 1156689
[No Abstract] [Full Text] [Related]
16. Luteinizing hormone, adrenal androgenesis, and polycystic ovarian disease.
Polansky S
Obstet Gynecol; 1975 Apr; 45(4):451-4. PubMed ID: 1121374
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
18. [Comparison between purified FSH and hMG for induction of ovulation in women with PCO syndrome].
Uemura T; Yoshimura Y; Ishikawa M; Asukai K; Minaguchi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jul; 41(7):923-6. PubMed ID: 2507714
[No Abstract] [Full Text] [Related]
19. Ovarian hyperthecosis in the adolescent patient.
Wentz AC; Gutai JP; Jones GS; Migeon CJ
J Pediatr; 1976 Mar; 88(3):488-93. PubMed ID: 1107505
[TBL] [Abstract][Full Text] [Related]
20. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
